EASD 2023
Evaluating the effects of interventions beyond weight loss with precise fat and muscle measurements via MRI
Two analyses have shed light on an important factor when evaluating treatments that significantly reduce bodyweight: their effect on muscle composition. For their multi center SURPASS-3 MRI study, Eli Lilly and Company selected AMRA® Researcher to measure muscle volume and muscle fat infiltration.
- Tirzepatide reduces muscle fat infiltration in people with type 2 diabetes
- Tirzepatide achieves significant weight loss without adverse effects on muscle composition
A randomised clinical trial
Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity
The effect of liraglutide, a GLP-1 agonist for treatment of type 2 diabetes and obesity, on muscle fat infiltration (MFI) was presented at EASD last year.
In this study, researchers used AMRA´s protocol to measure changes in MFI in response to treatment with liraglutide and lifestyle interventions. Viewers of this presentation will learn if liraglutide, in addition to significantly reducing body weight and visceral fat, also has an impact on MFI. This clinical study also investigates associations between changes in MFI and changes in cardiometabolic biomarkers, showing significant associations with biomarkers for heart failure and inflammation (such as NT-proBNP and CRP).
Accelerate your metabolic disease research
AMRA® Researcher is a body composition analysis tool, based on a rapid 10-minute MRI scan with the high reproducibility needed for use in multicenter clinical trials. AMRA® Researcher delivers fat distribution and muscle composition measurements with unrivaled accuracy and precision.
- Highly accurate, reproducible and precise MR imaging data
- Global and regional fat volumes, fat fractions and lean tissue volumes—with accurate anatomical classification
- Contextual insights with imaging data compared to normal ranges based on our massive body composition database
References
1. Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne). 2020;11:592373.
2. Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611-44.
3. Patel KV, Pandey A, Ayers C, J. L, Dahlqvist Leinhard O, Joshi PH, et al. Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity: a randomised clinical trial. Diabetologica. 2022;65(Suppl 1):S59.
4. Linge J, Neeland I, Dahlqvist Leinhard O, Sattar N, Fernandez Lando L, Bray R, et al. Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.
5. Sattar N, Linge J, Neeland I, Dahlqvist Leinhard O, Fernandez Lando L, Bray R, et al. Tirzepatide reduces muscle fat infiltration relative to insulin degludec in people with type 2 diabetes (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.
6. Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the Definition of Sarcopenia in the Presence of Aging and Obesity-Initial Results from UK Biobank. J Gerontol A Biol Sci Med Sci. 2020;75(7):1309-16.
7. Linge J, Nasr P, Sanyal AJ, Dahlqvist Leinhard O, Ekstedt M. Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP Rep. 2023;5(3):100663
8. Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist Leinhard O. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle. 2021;12(6):1513-26.
9. Linge J, Ekstedt M, Dahlqvist Leinhard O. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep. 2021;3(1):100197.